Solid Biosciences (SLDB) Income from Non-Controlling Interests (2017)

Solid Biosciences (SLDB) reported Income from Non-Controlling Interests of -$1.1 million for Q1 2017.

Solid Biosciences (SLDB) Income from Non-Controlling Interests (2017) Analysis & Trends

Solid Biosciences (SLDB) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$1.1 million in Q1 2017.

  • For the quarter ending Q1 2017, Income from Non-Controlling Interests changed N/A year-over-year to -$1.1 million; the trailing twelve-month figure through Dec 2017 stood at -$1.1 million (changed N/A YoY), and the FY2017 full-year result was -$1.1 million, up 52.55% from the prior year.
  • Income from Non-Controlling Interests steadied at -$1.1 million in Q1 2017.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$1.1 million in Q1 2017 to a low of -$1.1 million in Q1 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Solid Biosciences 871.35 Mn 871.35 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2017 -1.06 Mn